RPI ID: 2015-045-201

Innovation Summary:
This invention describes a 3D method for measuring cellular chirality, which is critical for early detection of diseases like cancer and developmental disorders. Cells are cultured in a multi-layered 3D substrate that mimics tissue environments more accurately than traditional 2D cultures. The system determines directional asymmetry (chirality) by analyzing orientation from cell nucleus to organelle across orthogonal planes. Changes in chirality can be linked to pathological conditions, offering a non-invasive method for identifying abnormal cellular behavior. The method also enables comparisons between healthy and diseased cells, improving the specificity of diagnosis. This platform can be used in toxicity screening, drug discovery, and personalized diagnostics. It opens new doors for cell-based screening technologies and chirality-informed therapeutic targeting.

Challenges / Opportunities:
Current diagnostic methods do not effectively account for the spatial orientation of cells, which can be an early indicator of disease. 2D culture systems fail to represent complex cell behaviors found in vivo. This invention fills that gap by offering a 3D analytical platform that directly measures cell directionality. It creates opportunities in preclinical testing, embryonic defect screening, and real-time assessment of drug toxicity. The approach may help refine diagnostics for cancer, congenital disorders, and immune dysfunctions.

Key Benefits / Advantages:
✔ Non-invasive 3D chirality measurement
✔ Higher specificity in diagnostics
✔ Supports comparative cell analysis

Applications:
• Cancer detection and monitoring
• Birth defect screening
• Personalized drug development

Keywords:
#cellchirality #3Dculture #earlydiagnosis #cellularimaging

Intellectual Property:
US Issued Patent 10,001,472 B2